Insilico Medicine
Insilico Medicine raises additional $37M in Series E extension to advance AI-discovered drug pipeline.
valuation undisclosed
Sources (1)
- Insilico Medicine news — Insilico Medicine primary
SovereignBio
Where the money moves in AI-biotech — the IPOs, partnerships, funding rounds and acquisitions building the field, placed on a timeline with the geopolitics (US · China · Japan · Korea · EU) that shape them. Every dollar figure names its source (today: the company's own investor-relations page or announcement; regulatory filings are not linked yet). Nothing is installed; nothing about you is collected.
This is the tool. Figures are drawn only from free public sources (no PitchBook / Crunchbase paid feeds), so the picture is deliberately partial — see the coverage gauge below. Editorial is CC BY 4.0; each figure carries its own citation. A native version, when it ships, adds offline use; it never gates the web.
5
Honest coverage: 5 events, a count, not a share
Built from free public sources, SovereignBio holds 5 capital events. Nobody publishes a count of all AI-biotech deals to divide by, so we show the number we have, not a percentage. We show what we can source and name what we can’t, so you can calibrate your conclusions. As of 2026-06-10.
What’s covered
- US-listed IPOs (SEC S-1 / 424 filings)
- Major announced partnerships with disclosed economics
- Funding rounds disclosed via press release
- Public M&A announcements
Known gaps
- Undisclosed private rounds (most pre-Series-B)
- Confidential pharma BD deals without press release
- Most China-domestic rounds with CN-only filings
- Private valuations between funding events
- Stealth-mode companies pre-launch
Money by kind, by year
Money raised from investors, money a partner paid upfront, and money only promised “up to” are different things, so each has its own chart and its own scale. They are never added together.
Data table
| Year | Raised from investors (USD) | Events |
|---|---|---|
| 2020 | $232M | 1 |
| 2021 | $436M | 1 |
| 2024 | $37M | 1 |
Data table
| Year | Paid upfront by a partner (USD) | Events |
|---|---|---|
| 2020 | none tracked | 0 |
| 2021 | none tracked | 0 |
| 2024 | $83M | 2 |
Data table
| Year | Promised “up to”, if milestones are met (USD) | Events |
|---|---|---|
| 2020 | none tracked | 0 |
| 2021 | none tracked | 0 |
| 2024 | $2.9B | 2 |
When a headline says a deal is worth $1.7B, look for the word “upfront”. For Isomorphic Labs and Eli Lilly it was $45M. The rest arrives only if milestones are met.
Region
Sector
Type
5 of 5 events
-
Series E $37M -
Partnership $45M Isomorphic Labs
Isomorphic Labs / Eli Lilly drug-discovery partnership: $45M upfront, up to $1.7B in milestones.
with Eli Lilly · $45M upfront · up to $1.7B milestones
Sources (1)
- Isomorphic Labs news — Isomorphic Labs primary
-
Partnership $38M Isomorphic Labs
Isomorphic Labs / Novartis drug-discovery partnership: $37.5M upfront, up to $1.2B in milestones.
with Novartis · $38M upfront · up to $1.2B milestones
Sources (1)
- Isomorphic Labs news — Isomorphic Labs primary
-
IPO $436M Recursion Pharmaceuticals
Recursion Pharmaceuticals IPO on NASDAQ (RXRX), pricing 24.24M shares at $18 (about $436M raised).
NASDAQ · $18/share · 24.24M shares
Sources (1)
- Recursion Investor Relations — Recursion Pharmaceuticals, Inc. primary
-
IPO $232M Schrödinger
Schrödinger IPO on NASDAQ (SDGR): 13.66M shares at $17 including the over-allotment (11.88M base), ~$232M raised.
NASDAQ · $17/share · 13.66M shares
Sources (1)
- Schrödinger Investor Relations — Schrödinger, Inc. primary
No events match these filters.